Obstructive
peripheral arterial occlusive disease (PAOD) of the inferior members is a
worldwide health problem and its prevalence is estimated in 27 million of
people in Europe and North America. PAOD development is a multifactorial
process with a variety of severe manifestations as ischemic rest pain,
ulcerations, and gangrene increasing the risk of claudication, poor wound
healing, limb amputation, and stroke. The therapy for PAOD has increased in thelast decades with the introduction of regenerative therapy.
The use of
stem-cells, vascular endothelial growth factor (VEGF), and fibroblast growth
factor FGF significantly improved symptoms and hemodynamics variables in the
treated limbs, as reported in the literature. Bone
marrow mononuclear cells (BMCs) or platelet rich plasma (PRP) therapies are
delivered locally into affected tissues and can contribute to the regeneration
of ischemic tissues and enhance the neovascularization of ischemic hindlimbs
through both, cellular and paracrine mechanisms. Read more...................
No comments:
Post a Comment